| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | Novartis Q2 profits recover as revenue mantle passes to newer medicines | ||
| 12:46 | Bristol Myers, NVIDIA join forces to build life science's 'most powerful' AI factory | ||
| 11:46 | EMA's CHMP grants PRIME status to AbelZeta's C-CAR168 | ||
| 10:46 | Halozyme and Incyte sign licence agreement for INCA033989 formulations | ||
| Mo | Novartis and Takeda drugs gain rare blood cancer routine use on NHS | ||
| Mo | Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal | ||
| Mo | UK biotech financing continues recovery trajectory on five-year Q2 high | ||
| Mo | Aptar unveils framework for injectable drug delivery systems | ||
| Fr | Bayer's heart failure drug bound for NHS on NICE recommendation | ||
| Fr | FDA grants traditional approval to Novartis' Fabhalta for IgAN | ||
| Fr | MSD wins FDA approval for cholesterol pill to help plug Keytruda void | ||
| Fr | JCVI issues recommendation on adolescent MenB vaccination in UK | ||
| Do | UK commits to pharma IP protection in Swiss trade deal | ||
| Do | Novo secures European approval for oral Wegovy to extend lead over Lilly | ||
| Do | Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover | ||
| Do | Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III | ||
| Do | Telix opens radiopharmaceutical facility in Australia for cancer treatment | ||
| Do | Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy | ||
| Mi | J&J raises FY26 outlook following positive Q2 | ||
| Mi | Women's health attracted record equity in 2025 as companies share capital | ||
| Mi | AAIC26: The role of biomarkers in primary care and early diagnostics | ||
| Mi | FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN | ||
| Mi | Innovent licenses IBI355 rights to Spero for up to $1.1bn | ||
| 14.07. | AstraZeneca pays up to $1.5bn to license Dizal Pharma's lung cancer drug | ||
| 14.07. | Novartis and Chai Discovery collaborate on antibody identification |